SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: TREND1, conix, Phaeton, $Pistol Pete$
Search This Board: 
Last Post: 5/28/2017 10:26:23 AM - Followers: 381 - Board type: Free - Posts Today: 3


Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.        

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Current Report Filing (8-k) 05/23/2017 05:25:24 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/22/2017 07:53:15 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/22/2017 07:51:45 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/22/2017 07:50:22 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/22/2017 07:49:19 PM
#23637  Sticky Note 1 AFREZZA has 586 CUSTOMERS BASED ON PAST TREND1 05/26/17 10:34:28 AM
#23541  Sticky Note Buffalo teacher a key advocate in breakthrough diabetes drug Phaeton 05/19/17 12:07:29 PM
#22592  Sticky Note $MNKD FLYNN JAMES E PICKED MANNKIND CORP (NASDAQ:MNKD) $Pistol Pete$ 04/21/17 03:34:59 PM
#23671   Yes that would be the same KC :-) Phaeton 05/28/17 10:26:23 AM
#23670   PPHM needs to move quick as competition in Hypi 05/28/17 10:00:51 AM
#23669   lots of insider buys. something going to happen harry crumb 05/28/17 08:42:57 AM
#23668   With 90 new sales reps how many patients Hypi 05/27/17 08:04:28 AM
#23667   My Dad.... 1 year now. Loves it. martind18 05/26/17 11:33:57 PM
#23666   KC? WHS 05/26/17 09:55:15 PM
#23665   col 7 = refills TREND1 05/26/17 09:35:10 PM
#23664 WHS 05/26/17 09:19:23 PM
#23663   deadaim TREND1 05/26/17 09:15:15 PM
#23662   Thank you quicksilver459 05/26/17 09:11:35 PM
#23661   Jim is the Managing Partner of Deerfield. He opticalalert_com 05/26/17 06:13:01 PM
#23660   * * $MNKD Video Chart 05-26-17 * * ClayTrader 05/26/17 04:54:37 PM
#23659   MNKD Many investors are testing the waters here gogoyears 05/26/17 04:52:12 PM
#23658   Yahoo shows 1/5 on 3/3 rahrah 05/26/17 04:36:34 PM
#23655   SORRY I always listen to the price. TREND1 05/26/17 03:35:59 PM
#23654   Yeah right lol. This is manipulated like Tbone88 05/26/17 03:23:04 PM
#23653   *****A close above 1.88 would be BULLISH. IMHO. TREND1 05/26/17 03:17:15 PM
#23652   Lmfao. Wtf was the point of that?! Tbone88 05/26/17 03:03:08 PM
#23651   Looks ready for next push. Good day especially considering no shorts 05/26/17 02:48:48 PM
#23650   Pump n dump. Hahahahaha you've been scammed Tbone88 05/26/17 01:52:57 PM
#23648   For a company that is supposed to be tyfoidhana 05/26/17 01:43:27 PM
#23647   Looking good MNKD. Many Green Day's ahead imo no shorts 05/26/17 01:33:30 PM
#23646   Bottom line this company should be worth at terragord7 05/26/17 12:23:21 PM
#23645   Anyone remember what the share price was before quicksilver459 05/26/17 12:10:08 PM
#23644   MNKD is booming! Great things coming for martind18 05/26/17 11:41:04 AM
#23643   Doubt it while crossing ma50 terragord7 05/26/17 11:13:48 AM
#23642   See you all next Friday. Bye for now. TREND1 05/26/17 11:04:51 AM
#23641   56 % for borrowed shares to go short. TREND1 05/26/17 11:03:36 AM
#23640   Did you notice the 3rd chart shows MNDK TREND1 05/26/17 10:54:08 AM
#23639   5/25/2017 17-0029 Area Business Manager Memphis TN WHS 05/26/17 10:53:02 AM
#23638   I was just thinking it was time for PARker1703 05/26/17 10:48:12 AM
#23637   1 AFREZZA has 586 CUSTOMERS BASED ON PAST TREND1 05/26/17 10:34:28 AM
#23636   nrx;102-109-105-104-125-124-133-134-123-142-117-155-141-164-149 Great achie WHS 05/26/17 10:24:14 AM
#23635   And another high volume day too! martind18 05/26/17 09:49:40 AM
#23634   Getting some coverage 9 breakthrough therapies for diabetes. Hypi 05/26/17 09:47:01 AM
#23633   I think of MNKD right now, as a tx_farmer 05/26/17 12:23:04 AM
#23632   Got it June 10 need to wait for extracts terragord7 05/25/17 10:17:35 PM
#23631   What is the date terragord7 05/25/17 08:36:45 PM
#23630   If I am correct someone already holding a tyfoidhana 05/25/17 08:36:41 PM
#23629   I know that Schwab is offering borrowed shares Kouka06 05/25/17 06:40:45 PM
#23628   You can never say in public you need terragord7 05/25/17 05:05:26 PM
#23627   * * $MNKD Video Chart 05-25-17 * * ClayTrader 05/25/17 04:53:01 PM
#23626   I agree as its not strictly individual investors. Hypi 05/25/17 12:15:00 PM
#23625   May be still coming.... martind18 05/25/17 12:04:20 PM
#23624   Interesting that with these high volume green days tyfoidhana 05/25/17 11:47:19 AM
#23623   I know you only get one post a martind18 05/25/17 10:45:54 AM
#23622   Good luck with your short position. The smart martind18 05/25/17 09:36:45 AM
#23621   The short interest is up by almost 2.5 DownWithPumpers 05/25/17 08:47:26 AM
#23620   Please list disadvantages as there are always at tx_farmer 05/25/17 12:21:46 AM
#23619   I absolutely love Afrezza. It has been a WHS 05/24/17 08:20:07 PM